Differential effect of glyburide (glibenclamide) and metformin on qt dispersion: a potential adenosine triphosphate sensitive k+ channel effect

Consequences of cardiac myocyte-specific ablation of KATPchannels in transgenic mice expressing dominant negative Kir6 subunits

“…One interpretation of these data is that there may be a small but significant activation of K ATP channels at near-physiological pacing rates in the nontransgenic mouse, which is not present in the transgenic mouse. Such an interpretation would be consistent with reports that K ATP channel blockade with glibenclamide increases the rat ventricular action potential duration under nonischemic conditions in some studies (3,40) and that glibenclamide caused QT prolongation in a clinical trial of patients with type II diabetes (20). However, a contribution of K ATP channels to the action potential is not always observed (16,33), Fig.…”

Management of Diabetes and Hyperglycemia in Hospitals

“…In individuals with type 2 diabetes, investigators found that glyburide increased QT dispersion (225). This effect, proposed to reflect risk for arrhythmias, was measured after 2 months of therapy with glyburide or metformin.…”

Prevalence and risk factors for prolonged QT interval and QT dispersion in patients with type 2 diabetes

“…The data in the literature on the relationship between the treatment of diabetes with sulfonylureas and QT prolongation are scarce. In a small group of subjects, Najeed and collaborators have found a significant increase in QTc interval (and QT dispersion) after 2 months of treatment with glibenclamide (from 433 ± 24 to 467 ± 24 ms), as opposed to patients receiving treatment with metformin [43]. …”